• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估细胞角蛋白标志物以区分前列腺良性和恶性组织。

Evaluation of cytokeratin markers to differentiate between benign and malignant prostatic tissue.

作者信息

Guinan P, Shaw M, Targonski P, Ray V, Rubenstein M

机构信息

Hektoen Institute for Medical Research, Cook County Hospital, Chicago IL 60612.

出版信息

J Surg Oncol. 1989 Nov;42(3):175-80. doi: 10.1002/jso.2930420309.

DOI:10.1002/jso.2930420309
PMID:2478835
Abstract

Cytokeratins are intermediate filaments found within basal and secretory epithelial cells. Antisera raised against cytokeratins are available but frequently differ in specificity. Many are incompletely characterized for their reactivity against epithelial components. Cytokeratin (Cyto) P is a polyclonal antisera specific for 56 and 64 kd cytokeratins. Cyto M is a pool of monoclonals reacting against 40, 46, 50, 52, 58, and 65-67 kd cytokeratins. Initially, utilizing immunohistologic techniques, we evaluated these two antisera for their ability to distinguish between prostatic tissues of benign (benign prostatic hypertrophy [BPH]) or malignant (carcinoma of the prostate [CAP]) origin in the 34 cases evaluated. Specimens were analyzed for both Cyto P and Cyto M reactivity, as well as for the degree of reactivity. Lastly, in an effort to determine the morphologic relationship of atypical hyperplasia (AH) with either BPH or CAP, nine additional prostate specimens were analyzed. Cyto P was reactive in 8 of 8 (100%) BPH specimens and in 2 of 26 (8%) CAP specimens. Mean Cyto P degree of reactivity in the positive specimens was greater in BPH than in CAP (2.6 vs. 1.0). Cyto M reactivity was present in 8 of 8 (100%) BPH specimens and in 23 of 25 (92%) CAP specimens. Mean Cyto M degree of reactivity in the positive specimens was greater in CAP than in BPH (3.6 vs. 2.8). Cyto P was reactive in 3 of 9 (33%) AH specimens, with a mean degree of reactivity of 2.7. Cyto M was reactive in 9 of 9 (100%) AH specimens, with a mean degree of reactivity of 3.9. Cyto P reacted with only the basal cells, whereas Cyto M reacted with basal as well as secretory cells. These differences appeared to be the result of the differential reactivity of basal cells, which are present in BPH but absent in CAP. In summary, Cyto P and Cyto M are potentially useful markers in differentiating BPH from CAP, and it appears that AH is immunohistopathologically related to both.

摘要

细胞角蛋白是存在于基底和分泌上皮细胞内的中间丝。针对细胞角蛋白制备的抗血清是可用的,但特异性常常不同。许多抗血清针对上皮成分的反应性特征不完全明确。细胞角蛋白(Cyto)P是一种针对56和64kd细胞角蛋白的多克隆抗血清。Cyto M是一组针对40、46、50、52、58以及65 - 67kd细胞角蛋白的单克隆抗体混合物。最初,我们利用免疫组织学技术,在34例评估病例中,评估这两种抗血清区分良性(良性前列腺增生[BPH])或恶性(前列腺癌[CAP])起源的前列腺组织的能力。对标本进行Cyto P和Cyto M反应性分析以及反应程度分析。最后,为了确定非典型增生(AH)与BPH或CAP的形态学关系,又分析了另外9例前列腺标本。Cyto P在8例(100%)BPH标本中的8例有反应,在26例CAP标本中的2例有反应。阳性标本中Cyto P的平均反应程度在BPH中高于CAP(2.6对1.0)。Cyto M反应性在8例(100%)BPH标本中的8例存在,在25例CAP标本中的23例(92%)存在。阳性标本中Cyto M的平均反应程度在CAP中高于BPH(3.6对2.8)。Cyto P在9例AH标本中的3例(33%)有反应,平均反应程度为2.7。Cyto M在9例AH标本中的9例(100%)有反应,平均反应程度为3.9。Cyto P仅与基底细胞反应,而Cyto M与基底细胞以及分泌细胞都反应。这些差异似乎是由于基底细胞反应性不同导致的,基底细胞存在于BPH中而不存在于CAP中。总之,Cyto P和Cyto M在区分BPH和CAP方面可能是有用的标志物,并且AH在免疫组织病理学上似乎与两者都相关。

相似文献

1
Evaluation of cytokeratin markers to differentiate between benign and malignant prostatic tissue.评估细胞角蛋白标志物以区分前列腺良性和恶性组织。
J Surg Oncol. 1989 Nov;42(3):175-80. doi: 10.1002/jso.2930420309.
2
Application of immunohistologic staining to develop a malignant index to aid in distinguishing benign from malignant prostatic tissue.应用免疫组织化学染色建立恶性指数,以辅助区分前列腺良性组织和恶性组织。
Prostate. 1989;14(4):383-8. doi: 10.1002/pros.2990140409.
3
An immunohistologic characterization of human prostatic atypical hyperplasia.人前列腺非典型增生的免疫组织学特征
Urol Res. 1990;18(3):193-6. doi: 10.1007/BF00295846.
4
Expression of some selected cytokeratins and Ki67 protein in prostatic tumor: can these be used as tumor markers.某些选定细胞角蛋白和Ki67蛋白在前列腺肿瘤中的表达:这些能否用作肿瘤标志物?
Pan Afr Med J. 2015 Jan 16;20:46. doi: 10.11604/pamj.2015.20.46.3926. eCollection 2015.
5
Changes in keratin expression during the development of benign prostatic hyperplasia.良性前列腺增生发展过程中角蛋白表达的变化。
Eur Urol. 1997;32(3):332-8.
6
Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.血管内皮生长因子受体Flt-1在前列腺良性、癌前及恶性组织中的表达。
J Urol. 2000 Aug;164(2):506-10.
7
Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues.良性、发育异常及恶性前列腺组织中表皮生长因子受体的差异免疫反应性
J Urol. 1993 Jan;149(1):170-3. doi: 10.1016/s0022-5347(17)36032-9.
8
Expression of c-kit and kit-ligand in benign and malignant prostatic tissues.c-kit和kit配体在前列腺良恶性组织中的表达。
Histol Histopathol. 2000 Apr;15(2):365-74. doi: 10.14670/HH-15.365.
9
Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.微血管密度作为一种分子标志物,用于识别前列腺癌的高级别前列腺上皮内瘤变前体。
Exp Mol Pathol. 2004 Oct;77(2):153-9. doi: 10.1016/j.yexmp.2004.04.005.
10
Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues.
Surg Oncol. 1994 Aug;3(4):237-42. doi: 10.1016/0960-7404(94)90039-6.

引用本文的文献

1
Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.
Urol Res. 1994;22(5):329-32. doi: 10.1007/BF00297204.
2
Keratin profiles in normal/hyperplastic prostates and prostate carcinoma.正常/增生性前列腺及前列腺癌中的角蛋白谱
Virchows Arch A Pathol Anat Histopathol. 1992;421(2):157-61. doi: 10.1007/BF01607049.